Printer Friendly

ANDRX ANNOUNCES NEW BOARD MEMBERS

 FORT LAUDERDALE, Fla., June 10 /PRNewswire/ -- Andrx Corporation, a pharmaceutical holding company recently formed by three ex-IVAX Corporation (AMEX: IVX) executives, announced today that its board of directors appointed Representative Elaine Bloom, Irwin (Win) Gerson, Herbert Grossman and Dean Michael Schwartz, Ph.D. as new members of the board.
 Representative Bloom is currently the Speaker Pro-Tempore of the Florida House of Representatives. She currently chairs the Joint Legislative Management Committee and serves on the Health Care, Aging and Human Services and Government Operations Committees. As chairperson of the Health Care Committee she authored Florida's 1992 Health Care Reform Act. Representative Bloom was also the author of Florida's International Banking Act and many other innovative measures. She is an active leader in the community and serves on the boards of many organizations. Over the years, she has been honored for her achievements, especially on behalf of women.
 Gerson is currently the chairman and chief executive officer of William Douglas McAdams, a healthcare marketing, communications and public relations company. Gerson is a member of the board of trustees of a number of academic institutions including Long Island University, Albany College of Pharmacy and the Arnold and Marie Schwartz College of Pharmacy. He continues to serve as a board member or director of various professional societies and is engaged in various leadership associations and panels.
 Grossman was the founding president and CEO of Zambon Corporation, the U.S. subsidiary of Zambon Group, an Italian multinational pharmaceutical company. He recently stepped down as chairman of the board. Grossman has over 35 years of experience in marketing, advertising, publishing, corporate planning and management in both the domestic and worldwide health care industry. He was responsible for the introduction and management of a number of the most widely prescribed pharmaceuticals, including Valium and the Sabin Polio Vaccine. Grossman is currently a health industry consultant and director of a number of publicly and privately held health care companies and is an officer and member of various professional organizations.
 Dr. Schwartz is currently the dean of the college of pharmacy and professor at the University of Florida. He has served as a consultant to various organizations, including Bristol-Myers Squibb (NYSE: BMY) and the Academy of Pharmaceutical Sciences. Dr. Schwartz has been an officer in numerous professional organizationals which include the American Pharmaceutical Association. He has received a number of professional honors and is the author of approximately 60 publications.
 Dr. Elliot F. Hahn, president of Andrx commented "We are very fortunate to have the opportunity to benefit from the diverse professional experience of our new board members. We look forward to working with them to achieve our goal of becoming a fully integrated pharmaceutical company."
 Andrx is a pharmaceutical holding company consisting of three operating division: Anda Generics, a generic distribution company, AndaSR Pharmaceuticals, a developer and manufacturer of controlled- release generic products and Aura Labs, a ethical pharmaceutical company.
 -0- 6/10/93
 /CONTACT: Elliot F. Hahn, Ph.D., president of Andrx Corporation, 305-584-0300/


CO: Andrx Corporation ST: Florida IN: MTC SU: PER

AW-JB -- FL017 -- 0847 06/10/93 17:23 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 10, 1993
Words:515
Previous Article:/C O R R E C T I O N -- HOME SHOPPING NETWORK/
Next Article:SUNAMERICA JOINS INVESTOR GROUP IN REHABILITATION PLAN FOR EXECUTIVE LIFE
Topics:


Related Articles
ANDRX ANNOUNCES EXECUTIVE APPOINTMENT
ANDRX RECEIVES TWO PATENTS FOR DELIVERY SYSTEMS
ANDRX ANNOUNCES ADDITIONAL EQUITY INVESTMENT BY WATSON PHARMACEUTICALS
ANDRX CORPORATION ANNOUNCES INITIAL PUBLIC OFFERING OF 2.2 MILLION SHARES OF COMMON STOCK
Rhone-Poulenc Rorer Pharmaceuticals, Inc. And Jagotec AG Dismiss Lawsuit Against Andrx
Andrx Licenses Cancer Therapy Adjunct To ASTA Medica AG
Class Action Suit Against ANDRX Corporation (Nasdaq: ADRX) Filed by Wechsler Harwood.
Wolf Haldenstein Adler Freeman and Herz LLP Commences Andrx Class Action.
Cauley Geller Announces Class Action Lawsuit Against Andrx Corporation On Behalf of Investors.
Watson to Acquire Andrx For $1.9 Billion, Creating the Third Largest Specialty Pharmaceutical Company In the U.S.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters